Blog

Galderma’s Nemluvio (nemolizumab) granted marketing authorisation in the United Kingdom and Switzerland for moderate to severe atopic dermatitis and prurigo nodularis

18 February 2025 - These are the first approvals of nemolizumab from countries within the Access Consortium framework, with regulatory review ...